Evidence map›Paper›PMID 26956845›Full record

ArticleEndocrine2016

Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome.

Suzan Tabur, Serdar Oztuzcu, Elif Oguz, Seniz Demiryürek, Hasan Dagli, Belgin Alasehirli, Mesut Ozkaya, Abdullah T Demiryürek

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Cofilin(s) and Mitochondria: Function Beyond Actin Dynamics.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. An emerging link between LIM domain proteins and nuclear receptors.Cellular and molecular life sciences : CMLS · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Suzan TaburDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey. suzan2471@yahoo.com.tr.
Serdar OztuzcuDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Elif OguzDepartment of Medical Pharmacology, Faculty of Medicine, Harran University, 63300, Sanliurfa, Turkey.
Seniz DemiryürekDepartment of Physiology, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Hasan DagliDepartment of Medical Biology, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Belgin AlasehirliDepartment of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Mesut OzkayaDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Abdullah T DemiryürekDepartment of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, 27310, Gaziantep, Turkey.
Gaziantep University · TRHarran University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metabolic syndrome (MetS) is a common multicomponent condition including abdominal obesity, dyslipidemia, hypertension, and hyperglycaemia. The aim of this study was to investigate the associations of the expression of a panel of signalling genes with the MetS in a Turkish population. A total of 54 MetS patients and 42 healthy controls with similar age and sex were included to this study. mRNA from blood samples was extracted, and real-time polymerase chain reaction was performed for gene expressions using a BioMark 96.96 dynamic array system. We observed marked increases in LIM kinase 2 (LIMK2) and cofilin 1 (CFL1) gene expressions in MetS patients. However, there were significant decreases in intercellular adhesion molecules 1 (ICAM1), ezrin (EZR), mitogen-activated protein kinase kinase 2 (MAP2K2), and nitric oxide synthase 3 (NOS3) gene expressions in MetS patients. Additionally, no marked changes were noted in other 15 genes studied. This is the first study to provide evidence that activation of LIMK2/CFL1 pathway may play an important role in MetS.

Indexed as

AdultCofilin 1Cytoskeletal ProteinsDown-RegulationEzrinFemaleGene ExpressionHumansIntercellular Adhesion Molecule-1Lim KinasesMaleMAP Kinase Kinase 2Metabolic SyndromeMiddle AgedNitric Oxide Synthase Type IIIUp-RegulationCofilin 1Cytoskeletal ProteinsEzrinICAM1 protein, humanIntercellular Adhesion Molecule-1LIMK2 protein, humanLim KinasesMAP Kinase Kinase 2Nitric Oxide Synthase Type IIINOS3 protein, humanCell signallingCofilinGene expressionLIM kinaseMetabolic syndrome

Identifiers

PMID26956845
OpenAlexW2296513228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.